Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Type

Guidance programme

Showing 1 to 7 of 7

TitleReference numberPublishedLast updated
Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapyTA1099
Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinomaTA1090
Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancerTA1041
Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancerTA1030
Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancerTA944
Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiationTA798
Durvalumab in combination for untreated extensive-stage small-cell lung cancer (terminated appraisal)TA662

Results per page

  1. 10
  2. 25
  3. 50
  4. All